Skye Bioscience

Skye Bio Obesity Drug Fails in Phase 2; Hopes Now Ride on Higher Doses and Combo Treatment

While Skye Bioscience said its drug nimacimab may yet achieve better weight loss results with higher doses, the company and analysts are interested in the drug’s potential to be combined with Novo Nordisk’s Wegovy. Skye’s drug is an antibody designed to preferentially target CB1 receptors in the gut, offering an alternative approach to activating GLP-1 receptors.

By Frank Vinluan

BioPharma, Pharma

Skye Bioscience Falls Short in Glaucoma Trial, But It’s Full Steam Ahead for Obesity Program

Skye Bioscience’s nimacimab blocks CB1, the same receptor targeted by an obesity drug candidate now in the hands of Novo Nordisk. But Skye contends its Phase 2-ready antibody drug has several advantages over the small molecule that joined Novo’s pipeline in a deal valued at $1 billion.

By Frank Vinluan

The Power of Real World Data to Study Women’s Health at Scale

Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!

By Veradigm and MedCity News

Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork

By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.

By Michael Blackman, MD, MBA Chief Medical Officer, Greenway Health®

Skye Bio Obesity Drug Fails in Phase 2; Hopes Now Ride on Higher Doses and Combo Treatment

Skye Bioscience Falls Short in Glaucoma Trial, But It’s Full Steam Ahead for Obesity Program

The Healthcare Payments Industry Has a Perception Problem